Developer docs
API playgroundTry for free, no card

Search company profiles

Velico Medical

Full company profile

uuid0002bfb

Namestring
Velico Medical
Company typeenum
Private
Founded yearint
1991
Descriptiontext

Velico Medical is a privately held medical technology company founded in 1991 and headquartered in Beverly, Massachusetts, specializing in spray dried plasma manufacturing systems. The company's core technology enables decentralized production of plasma products without cold chain infrastructure, addressing global plasma shortages and the limitations of traditional plasma storage and distribution. Velico's product portfolio comprises two systems: the veliPod™, a containerized manufacturing unit capable of producing up to 9,000 units of spray dried plasma annually and designed for deployment in frontline and remote settings, and the FrontlineODP™, an industrial-scale manufacturing system targeted at broader commercial and defense applications with planned capacity approaching one million units annually across planned facilities in North America, Europe, and the Indo-Pacific.

The company's primary customer segment is military and defense organizations, with the French Armed Forces Blood Transfusion Centre (CTSA) representing its first disclosed commercial customer following the world-first deployment of the veliPod in Paris in February 2026. Secondary targets include healthcare systems and emergency medical services requiring reliable plasma supply for disaster response and remote medical facilities. Velico's business model combines direct government/military sales with grant-based funding, having received $19 million from BARDA in 2017, an investment from New York Angels in 2024, and €1 million from the French Military in 2026. The company operates with 11-50 employees and is in an early commercialization phase, with revenue not publicly disclosed.

Velico's competitive positioning rests on its proprietary spray dried plasma technology and the logistical advantages of cold-chain-free, decentralized production. The technology has been validated through BARDA funding and military deployment, suggesting the company has navigated complex biodefense and pharmaceutical regulatory pathways. Distribution channels and pricing details are not publicly disclosed, but the company's go-to-market appears centered on direct engagement with government and military procurement channels, with planned expansion into broader healthcare and emergency response markets as manufacturing capacity scales.

Short descriptiontext

Velico Medical is a Beverly, Massachusetts-based medical technology company that develops spray dried plasma manufacturing systems — the veliPod and FrontlineODP — enabling decentralized, cold-chain-free plasma production for military, defense, and emergency healthcare customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBeverly, United States
HQ citystring
Beverly
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
spray dried plasma, blood transfusion products, plasma manufacturing systems, medical devices transfusion, decentralized plasma production
Industry2 codes
PRIMARYHLAIAHAI
Plasma Fractionation & Purification Manufacturing
SECONDARYHLAAAAAI
Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Medical Equipment and Supplies Manufacturing3391
Product category
Medical Devices — Blood and Plasma Manufacturing Systems
Social media profiles1 record
Cost components5 values
Technology or R&D, Supply Chain, Operations, Personnel, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1veliPod
Description

Containerized spray dried plasma manufacturing system designed for decentralized plasma production, enabling production of up to 9,000 units of spray dried plasma annually without cold chain requirements or heavy infrastructure.

aijourn.com
+1 more record
Core offering1 text field

Velico Medical designs, develops, and manufactures proprietary spray dried plasma manufacturing systems — the veliPod™ containerized system for military/frontline deployment and the FrontlineODP™ industrial-scale system for broader commercial and defense use. The systems enable decentralized production of spray dried plasma without cold chain requirements or heavy infrastructure, supporting trauma care, emergency transfusion, and national medical preparedness.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Produces up to 9,000 units of spray dried plasma annually per veliPod system
+2 more records
Product overview1 text field

Velico Medical offers a portfolio of spray dried plasma manufacturing systems comprising the veliPod™ for military deployment and the FrontlineODP™ for broader commercial and defense applications. Both products eliminate cold chain storage requirements and heavy infrastructure dependencies, enabling decentralized plasma production. The veliPod™ is a compact, containerized system deployed by militaries, while the FrontlineODP™ represents the company's scaled manufacturing platform designed for near-million unit annual capacity across multiple geographic regions.

Product and service2 records
1veliPod™
CategoryPlasma Manufacturing System — Military / Decentralized
Description

Containerized spray dried plasma manufacturing system designed for military deployment. The veliPod enables production of up to 9,000 units of spray dried plasma annually without cold chain requirements or heavy infrastructure, supporting battlefield trauma care, military medical preparedness, and remote plasma supply. It is intended for armed forces blood transfusion centers and defense medical programs.

2FrontlineODP™ Spray Dried Plasma Manufacturing System
CategoryPlasma Manufacturing System — Commercial / Industrial-Scale
Description

Industrial-scale spray dried plasma manufacturing system for commercial and defense use. The FrontlineODP supports production of nearly one million plasma units annually, with planned manufacturing facilities in North America, Europe, and the Indo-Pacific, and is intended for healthcare systems, emergency medical services, and defense customers requiring large-scale decentralized plasma supply.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-17
Description

France's Armed Forces Blood Transfusion Centre (CTSA) in Paris received Velico Medical's first veliPod containerized spray dried plasma manufacturing system on February 17, 2026. This represents a world-first deployment of decentralized plasma production technology for military use, marking a strategic partnership in advancing military trauma care capabilities.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Plasma-derived therapy manufacturer with significant military and rare disease franchises, including collaborations on dried plasma products. Comparable as a downstream plasma therapeutics company operating in overlapping end markets and with prior interest in decentralized/dried plasma formats.

TypeBroad incumbent
Description

Global plasma fractionator and manufacturer of plasma-derived therapies, with deep relationships with blood collection centers. Comparable as a large incumbent that depends on upstream plasma supply technologies of the kind Velico is developing.

TypeDirect peer
Description

Developer of the INTERCEPT pathogen reduction system for platelets, plasma, and whole blood, sold to blood centers and military/defense customers. Comparable as a blood-product safety and processing technology company targeting the same transfusion medicine and military trauma end markets.

TypeBroad incumbent
Description

One of the world's largest plasma fractionators, producing plasma-derived therapeutics (immunoglobulins, albumin, clotting factors). Comparable as a major player in the plasma-derived therapy value chain that Velico's spray dried plasma supply could feed into.

TypeBroad incumbent
Description

Major diversified healthcare company supplying blood collection bags, processing solutions, and transfusion medicine equipment globally, including products for plasma production. Comparable as a broad incumbent in the same end-to-end plasma supply chain.

TypeDirect peer
Description

Specialized manufacturer of blood bag systems, plasma processing devices, and pathogen reduction/inactivation solutions for transfusion medicine. Comparable as a focused supplier of plasma manufacturing and processing technologies to blood centers and defense customers.

TypeRegional player
Description

Manufacturer of medical cold chain equipment including blood bank refrigerators and plasma freezers used by militaries and humanitarian organizations. Comparable as a supplier of blood/plasma logistics infrastructure to military and emergency response customers, even though Velico's value proposition is to displace cold chain rather than support it.

TypeDirect peer
Description

Global leader in blood component collection, processing, and storage equipment, including apheresis systems and pathogen reduction technologies. Directly comparable as a supplier of capital equipment and disposables used to manufacture and deliver blood/plasma products to hospitals, blood banks, and military medical services.

TypeBroad incumbent
Description

Privately held global plasma fractionator producing immunoglobulins, coagulation factors, and other plasma-derived therapies. Comparable as a major downstream consumer of plasma supply technologies and as a potential strategic partner or acquirer of plasma supply innovations.

10Haemonetics Corporation
TypeDirect peer
Description

Manufacturer of blood and plasma component collection and processing equipment, including plasma collection systems sold to source plasma collectors. Comparable as a medical device company whose capital equipment underpins the blood/plasma supply chain.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Velico Medical

Medical Devices — Blood and Plasma Manufacturing Systemsvelicomedical.com

Velico Medical is a Beverly, Massachusetts-based medical technology company that develops spray dried plasma manufacturing systems — the veliPod and FrontlineODP — enabling decentralized, cold-chain-free plasma production for military, defense, and emergency healthcare customers.

What Velico Medical does

Velico Medical is a privately held medical technology company founded in 1991 and headquartered in Beverly, Massachusetts, specializing in spray dried plasma manufacturing systems. The company's core technology enables decentralized production of plasma products without cold chain infrastructure, addressing global plasma shortages and the limitations of traditional plasma storage and distribution. Velico's product portfolio comprises two systems: the veliPod™, a containerized manufacturing unit capable of producing up to 9,000 units of spray dried plasma annually and designed for deployment in frontline and remote settings, and the FrontlineODP™, an industrial-scale manufacturing system targeted at broader commercial and defense applications with planned capacity approaching one million units annually across planned facilities in North America, Europe, and the Indo-Pacific.

The company's primary customer segment is military and defense organizations, with the French Armed Forces Blood Transfusion Centre (CTSA) representing its first disclosed commercial customer following the world-first deployment of the veliPod in Paris in February 2026. Secondary targets include healthcare systems and emergency medical services requiring reliable plasma supply for disaster response and remote medical facilities. Velico's business model combines direct government/military sales with grant-based funding, having received $19 million from BARDA in 2017, an investment from New York Angels in 2024, and €1 million from the French Military in 2026. The company operates with 11-50 employees and is in an early commercialization phase, with revenue not publicly disclosed.

Velico's competitive positioning rests on its proprietary spray dried plasma technology and the logistical advantages of cold-chain-free, decentralized production. The technology has been validated through BARDA funding and military deployment, suggesting the company has navigated complex biodefense and pharmaceutical regulatory pathways. Distribution channels and pricing details are not publicly disclosed, but the company's go-to-market appears centered on direct engagement with government and military procurement channels, with planned expansion into broader healthcare and emergency response markets as manufacturing capacity scales.

Velico Medical firmographics

Firmographics
Name
Velico Medical
Website
https://velicomedical.com
Company type
Private
Founded year
1991
Operating status
Operating
Headcount range
11–50 employees
Short description
Velico Medical is a Beverly, Massachusetts-based medical technology company that develops spray dried plasma manufacturing systems — the veliPod and FrontlineODP — enabling decentralized, cold-chain-free plasma production for military, defense, and emergency healthcare customers.
Ownership category
akta.pro rank

Velico Medical industry classification

Industry
Product category
Medical Devices — Blood and Plasma Manufacturing Systems
NAICS
Medical Equipment and Supplies Manufacturing (3391)
akta.pro industry
PRIMARYHLAIAHAI
Plasma Fractionation & Purification Manufacturing
SECONDARYHLAAAAAI
Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Spray dried plasma
  • Blood transfusion products
  • Plasma manufacturing systems
  • Medical devices transfusion
  • Decentralized plasma production

Where Velico Medical is headquartered

Location

Headquarters

HQ city
Beverly
HQ country
United States
HQ region
North America

Markets served

Velico Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Operations, Personnel, Infrastructure

Velico Medical product offering

Product offering

Core offering

Velico Medical designs, develops, and manufactures proprietary spray dried plasma manufacturing systems — the veliPod™ containerized system for military/frontline deployment and the FrontlineODP™ industrial-scale system for broader commercial and defense use. The systems enable decentralized production of spray dried plasma without cold chain requirements or heavy infrastructure, supporting trauma care, emergency transfusion, and national medical preparedness.

Product overview

Velico Medical offers a portfolio of spray dried plasma manufacturing systems comprising the veliPod™ for military deployment and the FrontlineODP™ for broader commercial and defense applications. Both products eliminate cold chain storage requirements and heavy infrastructure dependencies, enabling decentralized plasma production. The veliPod™ is a compact, containerized system deployed by militaries, while the FrontlineODP™ represents the company's scaled manufacturing platform designed for near-million unit annual capacity across multiple geographic regions.

Differentiator

Problem solved

Functional benefit

Brands

  • veliPod: Containerized spray dried plasma manufacturing system designed for decentralized plasma production, enabling production of up to 9,000 units of spray dried plasma annually without cold chain requirements or heavy infrastructure.
  • FrontlineODP

Products and services

  • veliPod™ Containerized spray dried plasma manufacturing system designed for military deployment. The veliPod enables production of up to 9,000 units of spray dried plasma annually without cold chain requirements or heavy infrastructure, supporting battlefield trauma care, military medical preparedness, and remote plasma supply. It is intended for armed forces blood transfusion centers and defense medical programs.
  • FrontlineODP™ Spray Dried Plasma Manufacturing System Industrial-scale spray dried plasma manufacturing system for commercial and defense use. The FrontlineODP supports production of nearly one million plasma units annually, with planned manufacturing facilities in North America, Europe, and the Indo-Pacific, and is intended for healthcare systems, emergency medical services, and defense customers requiring large-scale decentralized plasma supply.

Quantifiable outcome

  • Produces up to 9,000 units of spray dried plasma annually per veliPod system
  • +2 more outcomes

Companies that use Velico Medical

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Velico Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Velico Medical partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • French Armed Forces Blood Transfusion Centre (CTSA)coreStrategic or Co-development Partner · 17 February 2026France's Armed Forces Blood Transfusion Centre (CTSA) in Paris received Velico Medical's first veliPod containerized spray dried plasma manufacturing system on February 17, 2026. This represents a world-first deployment of decentralized plasma production technology for military use, marking a strategic partnership in advancing military trauma care capabilities.

Scale indicators4 records

Recent moves9 records

Expansion highlights5 records

Velico Medical competitors and assessment

Company assessment

Broad incumbents

  • Kedrion Biopharma: Plasma-derived therapy manufacturer with significant military and rare disease franchises, including collaborations on dried plasma products. Comparable as a downstream plasma therapeutics company operating in overlapping end markets and with prior interest in decentralized/dried plasma formats.
  • CSL Behring: Global plasma fractionator and manufacturer of plasma-derived therapies, with deep relationships with blood collection centers. Comparable as a large incumbent that depends on upstream plasma supply technologies of the kind Velico is developing.
  • Grifols: One of the world's largest plasma fractionators, producing plasma-derived therapeutics (immunoglobulins, albumin, clotting factors). Comparable as a major player in the plasma-derived therapy value chain that Velico's spray dried plasma supply could feed into.
  • Fresenius Kabi (Transfusion Medicine): Major diversified healthcare company supplying blood collection bags, processing solutions, and transfusion medicine equipment globally, including products for plasma production. Comparable as a broad incumbent in the same end-to-end plasma supply chain.
  • Octapharma: Privately held global plasma fractionator producing immunoglobulins, coagulation factors, and other plasma-derived therapies. Comparable as a major downstream consumer of plasma supply technologies and as a potential strategic partner or acquirer of plasma supply innovations.

Direct peers

  • Cerus Corporation: Developer of the INTERCEPT pathogen reduction system for platelets, plasma, and whole blood, sold to blood centers and military/defense customers. Comparable as a blood-product safety and processing technology company targeting the same transfusion medicine and military trauma end markets.
  • MacoPharma: Specialized manufacturer of blood bag systems, plasma processing devices, and pathogen reduction/inactivation solutions for transfusion medicine. Comparable as a focused supplier of plasma manufacturing and processing technologies to blood centers and defense customers.
  • Terumo BCT: Global leader in blood component collection, processing, and storage equipment, including apheresis systems and pathogen reduction technologies. Directly comparable as a supplier of capital equipment and disposables used to manufacture and deliver blood/plasma products to hospitals, blood banks, and military medical services.
  • Haemonetics Corporation: Manufacturer of blood and plasma component collection and processing equipment, including plasma collection systems sold to source plasma collectors. Comparable as a medical device company whose capital equipment underpins the blood/plasma supply chain.

Regional players

  • B Medical Systems: Manufacturer of medical cold chain equipment including blood bank refrigerators and plasma freezers used by militaries and humanitarian organizations. Comparable as a supplier of blood/plasma logistics infrastructure to military and emergency response customers, even though Velico's value proposition is to displace cold chain rather than support it.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Velico Medical social profiles

Digital presence

Velico Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Velico Medical leadership team

Management profile

Number of profiles

Profiles6 records

Velico Medical funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Velico Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Velico Medical

What does Velico Medical do?

Velico Medical designs, develops, and manufactures proprietary spray dried plasma manufacturing systems — the veliPod™ containerized system for military/frontline deployment and the FrontlineODP™ industrial-scale system for broader commercial and defense use. The systems enable decentralized production of spray dried plasma without cold chain requirements or heavy infrastructure, supporting trauma care, emergency transfusion, and national medical preparedness.

When was Velico Medical founded?

Velico Medical was founded in 1991. It employs 11 to 50 people.

Where is Velico Medical based?

Velico Medical is headquartered in Beverly, United States, in the North America region.

Who are Velico Medical's main competitors?

Broad incumbents on record are Kedrion Biopharma, CSL Behring, Grifols, Fresenius Kabi (Transfusion Medicine) and Octapharma. Direct peers are Cerus Corporation, MacoPharma, Terumo BCT and Haemonetics Corporation. B Medical Systems is listed as a regional player.

Does Velico Medical have an API?

No public API is recorded for Velico Medical.

What industry is Velico Medical in?

Velico Medical's product category is Medical Devices — Blood and Plasma Manufacturing Systems. Its primary akta.pro industry code is HLAIAHAI, Plasma Fractionation & Purification Manufacturing, with a secondary code of HLAAAAAI, Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors). Its NAICS code is 3391.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The TelegraphBritain pioneers new dried blood products for the modern battlefieldBritain is developing spray-dried plasma, a powdered blood product that can be rehydrated with water, to address battlefield logistics. The NHS and Ministry of Defence signed a partnership with Velico Medical to create it, aiming to replace refrigerated wet blood products. The product could be used in future conflicts like Ukraine.AijournA World First: A Major Innovation in Blood TransfusionOn February 17, 2026, France's Armed Forces Blood Transfusion Centre (CTSA) in Paris received Velico Medical's first veliPod™, a containerized spray dried plasma manufacturing system, marking a world-first deployment of decentralized plasma production technology for military use. The veliPod™ enables the French Military to produce up to 9,000 units of spray dried plasma annually without cold chain requirements or heavy infrastructure, representing a significant advancement in trauma care capabilities and national medical preparedness. Velico received an initial €1 million investment from the French Military, which underscores the strategic importance of this technology in addressing global plasma shortages.PR NewswireA World First: A Major Innovation in Blood TransfusionOn February 17, 2026, Velico delivered its first veliPod™ containerized spray-dried plasma manufacturing system to France's Armed Forces Blood Transfusion Centre (CTSA) in Paris, marking a world-first milestone in decentralized plasma production for military use. The veliPod™ system enables on-site production of spray-dried plasma that can be stored at ambient temperatures and rehydrated in under 2.5 minutes, with capacity to produce up to 9,000 units per year, eliminating cold chain constraints. The French Military made an initial €1 million investment in the technology, which has completed a Phase I clinical trial demonstrating a strong safety profile, positioning this deployment as a potential model for broader global adoption of decentralized plasma manufacturing.BioSpaceA World First: A Major Innovation in Blood TransfusionOn February 17, 2026, France's Armed Forces Blood Transfusion Centre received Velico's veliPod, a containerised spray dried plasma manufacturing system. The system can produce up to 9,000 units annually, addressing global plasma shortages of fewer than 50,000 units yearly. The French military's adoption marks a step toward national self-sufficiency in plasma production.PR NewswireThe American National Red Cross Teams Up With Velico Medical In The Blood Center Education ProgramVelico Medical has announced a collaboration with the American National Red Cross through the Blood Center Education Program, allowing strategic partners to evaluate the FrontlineODP spray drying plasma system for potential integration into blood component operations. The system aims to make plasma more accessible for first responders, rural hospitals, military use, and mass casualty events where frozen plasma is unavailable or impractical due to cold chain limitations. The program is funded in part by federal funds from the Department of Health and Human Services under a BARDA contract.PR NewswireThe American National Red Cross Teams Up With Velico Medical In The Blood Center Education ProgramVelico Medical announced a collaboration with the American National Red Cross through the Blood Center Education Program, allowing Red Cross blood centers to evaluate Velico's FrontlineODP spray drying plasma system and provide operational feedback. The FrontlineODP system is designed to produce point-of-care dried plasma for use in settings where frozen plasma is unavailable, including rural hospitals, ambulances, and military applications. The partnership aims to advance dry plasma research and expand access to lifesaving blood products in the US and globally.PR NewswireVelico Medical launches Blood Center Education Program with South Texas Blood & TissueVelico Medical launched its Blood Center Education Program (BCEP) in partnership with South Texas Blood & Tissue to gather feedback on its FrontlineODP spray-dried plasma system. This collaboration aims to advance the development of a point-of-care plasma product that can be stored at ambient temperatures, addressing logistical challenges in emergency and rural medical settings.PR NewswireVelico Medical launches Blood Center Education Program with South Texas Blood & TissueVelico Medical has launched its Blood Center Education Program (BCEP) at South Texas Blood & Tissue, a subsidiary of BioBridge Global, representing the first collaboration of its kind in the nation. The program will generate customer feedback on Velico's FrontlineODP system, which uses spray drying technology to produce powdered plasma that can be stored at ambient temperature and reconstituted on-scene for transfusions. The system aims to improve plasma availability for first responders, rural hospitals, military medics, and mass casualty situations where current frozen plasma products are impractical due to cold chain logistics and short shelf life.PR NewswireVelico Medical achieves two significant milestones in developing spray dried plasma for lifesaving point-of-care transfusionsVelico Medical received FDA approval to begin Phase-I human clinical trials for its FrontlineODP™ spray-dried plasma system, a point-of-care plasma product that can be stored at ambient temperature and reconstituted on-scene for transfusions. BARDA simultaneously executed a new contract (#75A50121C00059) with the company providing $20 million in initial funding, with potential follow-on options totaling up to $74.3 million, to support continued R&D, manufacturing scale-up, and commercial preparation. The technology addresses critical limitations of current frozen plasma products by eliminating cold chain logistics requirements and extending shelf stability, potentially enabling first responders, rural hospitals, and military medical personnel to administer plasma transfusions in settings where frozen products are unavailable or impractical.